{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:52:38Z","timestamp":1784166758274,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jcin.2024.03.027","type":"journal-article","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T15:06:25Z","timestamp":1712502385000},"page":"1356-1370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["P2Y12 Inhibition in Patients Requiring Oral\u00a0Anticoagulation After Percutaneous\u00a0Coronary Intervention"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9567-3253","authenticated-orcid":false,"given":"Luis","family":"Ortega-Paz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3253-5961","authenticated-orcid":false,"given":"Wilbert","family":"Bor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8503-5736","authenticated-orcid":false,"given":"Francesco","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wout W.A.","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Rollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2591-6010","authenticated-orcid":false,"given":"Salvatore","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-182X","authenticated-orcid":false,"given":"Mattia","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latonya","family":"Been","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghussan","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awss","family":"Shalhoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroutioun","family":"Garabedian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tala","family":"Al Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6697-819X","authenticated-orcid":false,"given":"Ekin","family":"Uzunoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres M.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva","family":"Suryadevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Soffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1685-6690","authenticated-orcid":false,"given":"Madeline K.","family":"Mahowald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin Y.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin M.","family":"Zenni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fladia","family":"Phoenix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi A.","family":"Ajjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurrien M.","family":"ten Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2024.03.027_bib1","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2024.03.027_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2019.05.016","article-title":"Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review","volume":"74","author":"Capodanno","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.03.027_bib3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.03.027_bib4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2024.03.027_bib5","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.03.027_bib6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.03.027_bib7","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.03.027_bib8","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2024.03.027_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.03.027_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.03.027_bib11","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.03.027_bib12","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1161\/01.CIR.101.24.2823","article-title":"Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans","volume":"101","author":"Cadroy","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.03.027_bib13","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2024.03.027_bib14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2217\/pgs-2022-0057","article-title":"Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention","volume":"23","author":"Galli","year":"2022","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jcin.2024.03.027_bib15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1093\/eurheartj\/ehad362","article-title":"Personalised antiplatelet therapies for coronary artery disease: what the future holds","volume":"44","author":"Capodanno","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.03.027_bib16","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score","volume":"13","author":"Angiolillo","year":"2020","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2024.03.027_bib17","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1093\/eurheartj\/ehac294","article-title":"Great debate: triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1\u00a0week","volume":"43","author":"De Caterina","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.03.027_bib18","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2024.03.027_bib19","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCULATIONAHA.118.034790","article-title":"Study of two dose regimens of ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease","volume":"138","author":"Orme","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.03.027_bib20","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/CIRCULATIONAHA.120.048770","volume":"142","author":"Franchi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.03.027_bib21","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jacc.2015.12.062","article-title":"Platelet inhibition with ticagrelor 60\u00a0mg versus 90\u00a0mg twice daily in the PEGASUS-TIMI 54 trial","volume":"67","author":"Storey","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.03.027_bib22","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.03.027_bib23","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y(12) receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.03.027_bib24","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison","volume":"72","author":"Capodanno","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.03.027_bib25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcin.2022.10.034","article-title":"Cangrelor in patients with coronary artery disease pretreated with ticagrelor: The Switching Antiplatelet (SWAP)-5 study","volume":"16","author":"Franchi","year":"2023","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2024.03.027_bib26","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1016\/j.jcin.2023.08.009","article-title":"Switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention: the Switching Antiplatelet-6 (SWAP-6) study","volume":"16","author":"Franchi","year":"2023","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2024.03.027_bib27","first-page":"763","article-title":"Pharmacodynamic effects of vorapaxar in patients with and without diabetes mellitus: results of the OPTIMUS-5 study","volume":"4","author":"Franchi","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jcin.2024.03.027_bib28","article-title":"Pharmacodynamic effects of vorapaxar in prior myocardial infarction patients treated with potent oral P2Y(12) receptor inhibitors with and without aspirin: results of the VORA-PRATIC study","volume":"9","author":"Franchi","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jcin.2024.03.027_bib29","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1161\/CIRCULATIONAHA.118.033983","article-title":"Pharmacodynamic effects of switching from ticagrelor to clopidogrel in patients with coronary artery disease: results of the SWAP-4 study","volume":"137","author":"Franchi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.03.027_bib30","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","article-title":"Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"139","author":"Franchi","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.03.027_bib31","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/CIRCULATIONAHA.116.023402","article-title":"Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: the OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 study","volume":"134","author":"Franchi","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.03.027_bib32","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1161\/ATVBAHA.107.153221","article-title":"Heritability of clot formation, morphology, and lysis: the EuroCLOT study","volume":"27","author":"Carter","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jcin.2024.03.027_bib33","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1161\/ATVBAHA.111.236786","article-title":"Clot architecture is altered in abdominal aortic aneurysms and correlates with aneurysm size","volume":"31","author":"Scott","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jcin.2024.03.027_bib34","first-page":"419","article-title":"Prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes: results of a randomized pharmacodynamic study in a feasibility investigation of rapid genetic testing","volume":"5","author":"Franchi","year":"2020","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jcin.2024.03.027_bib35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/pgs-2017-0028","article-title":"Institutional profile: University of Florida Health Personalized Medicine Program","volume":"18","author":"Cavallari","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jcin.2024.03.027_bib36","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.03.027_bib37","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.03.027_bib38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j..2002.384.doc.x","article-title":"Design and analysis of pilot studies: recommendations for good practice","volume":"10","author":"Lancaster","year":"2004","journal-title":"J\u00a0Eval Clin Pract"},{"key":"10.1016\/j.jcin.2024.03.027_bib39","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jacc.2016.02.045","article-title":"Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study","volume":"67","author":"Rollini","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.03.027_bib40","article-title":"ABCD-GENE score and clinical outcomes following percutaneous coronary intervention: insights from the TAILOR-PCI trial","volume":"11","author":"Capodanno","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jcin.2024.03.027_bib41","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/STROKEAHA.120.033049","article-title":"Application of age, body mass index, chronic kidney disease, diabetes, and genotyping score for efficacy of clopidogrel: secondary analysis of the CHANCE trial","volume":"53","author":"Dai","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.jcin.2024.03.027_bib42","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s12265-022-10255-8","article-title":"Performance of the ABCD-GENE score for predicting clinical outcomes in clopidogrel-treated patients with ACS","volume":"15","author":"Jin","year":"2022","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.jcin.2024.03.027_bib43","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/cpt.2612","article-title":"Impact of the ABCD-GENE score on clopidogrel clinical effectiveness after PCI: a multi-site, real-world investigation","volume":"112","author":"Thomas","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2024.03.027_bib44","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(17)32279-1","article-title":"Dual antiplatelet therapy guided by platelet function testing","volume":"390","author":"Angiolillo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2024.03.027_bib45","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehz059","article-title":"Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial","volume":"40","author":"Oldgren","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.03.027_bib46","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jacc.2019.11.056","article-title":"Ticagrelor with or without aspirin after PCI: the TWILIGHT platelet substudy","volume":"75","author":"Baber","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.03.027_bib47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2\u00a0months of dual antiplatelet therapy with 12\u00a0months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jcin.2024.03.027_bib48","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial","volume":"149","author":"Natsuaki","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.03.027_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17512433.2023.2154651","article-title":"Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications","volume":"16","author":"Galli","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jcin.2024.03.027_bib50","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1055\/a-1730-8725","article-title":"Pharmacodynamic profiles of dual-pathway inhibition with or without clopidogrel versus dual antiplatelet therapy in patients with atherosclerotic disease","volume":"122","author":"Galli","year":"2022","journal-title":"Thromb Haemost"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879824006319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879824006319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:32:04Z","timestamp":1749515524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879824006319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1936879824006319"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2024.03.027","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"P2Y12 Inhibition in Patients Requiring Oral\u00a0Anticoagulation After Percutaneous\u00a0Coronary Intervention","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2024.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}